Lupin gets $25 million from AbbVie

01 Jul 2023 Evaluate

Lupin has received $25 million (around Rs 205 crore) from AbbVie Inc for meeting a key development milestone for a product to treat hematological cancers. The company has achieved a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program that is partnered with AbbVie Inc towards treatment across a range of hematological cancers. As part of the agreement, the company has received $25 million from AbbVie for initiation of Phase 1 clinical studies successfully.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2140.40 -25.70 (-1.19%)
21-Jan-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.10
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 875.10
Lupin 2140.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×